|
gptkbp:instanceOf
|
gptkb:biotechnology
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:ChemoCentryx
gptkb:Horizon_Therapeutics
gptkb:Immunex
gptkb:Onyx_Pharmaceuticals
|
|
gptkbp:CEO
|
gptkb:Robert_A._Bradway
|
|
gptkbp:dividendPaying
|
yes
|
|
gptkbp:foundedYear
|
1980
|
|
gptkbp:founder
|
gptkb:George_Rathmann
|
|
gptkbp:fullName
|
gptkb:Amgen_Inc.
|
|
gptkbp:hasPatent
|
biosimilars
biologic drugs
|
|
gptkbp:headquartersLocation
|
gptkb:Thousand_Oaks,_California,_United_States
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US0311621009
|
|
gptkbp:listedOn
|
gptkb:Fortune_500
|
|
gptkbp:logo
|
Amgen_logo.svg
|
|
gptkbp:marketCap
|
over $100 billion
|
|
gptkbp:memberOf
|
gptkb:NASDAQ-100
gptkb:S&P_500
|
|
gptkbp:netIncome
|
over $6 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Aimovig
gptkb:Aranesp
gptkb:Enbrel
gptkb:Epogen
gptkb:Neulasta
gptkb:Prolia
gptkb:Repatha
gptkb:Xgeva
|
|
gptkbp:numberOfEmployees
|
2023
~25,200
|
|
gptkbp:product
|
biopharmaceuticals
|
|
gptkbp:researchInterest
|
gptkb:cardiovascular_disease
neuroscience
oncology
nephrology
inflammation
bone health
|
|
gptkbp:revenue
|
over $26 billion (2023)
|
|
gptkbp:SIC
|
2836
|
|
gptkbp:stockSymbol
|
gptkb:AMGN
|
|
gptkbp:subsidiary
|
gptkb:Amgen_Ventures
gptkb:deCODE_genetics
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ
|
|
gptkbp:website
|
https://www.amgen.com/
|
|
gptkbp:bfsParent
|
gptkb:Amgen
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AMGN
|